orlistat Articles

Roche earnings hit new heights, Humer defends development pipeline

17 August 2000

US DTC spending set to pass $2 billion in 2000; COX-2 inhibitors lead in 1st

14 August 2000

Stock Commentary Europe

13 July 2000

MSDW explores US prescription sales in major therapeutic areas

6 July 2000

New leading pharma market forecasts to 2009 from Decision Resources

5 July 2000

Roche gives "sales warning" due to slow-down in Xenical revenues

26 June 2000

Stock Commentary Europe

8 June 2000

Top-selling drugs in Nordic countries

1 June 2000

Roche withdraws Euro filing for Tamiflu, but gains Herceptin backing

26 May 2000

Achieving synergy through diversity; focus on XiMed Group of the UK

24 May 2000

Roche says it is open to acquisitions/alliances

10 May 2000

US pharma promo spending up 11% to $13.9 billion in 1999, with DTC up 40%

25 April 2000

Xenical approved for sale in Australia

19 April 2000

XiMed reports progress for 1999

14 April 2000

Roche upbeat on pipeline despite problems with Trocade and Bonviva

13 April 2000

Pharma sales drive Roche growth in Q1

13 April 2000

Net income at Roche rises 15% in 1999, bolstered by Genentech

3 April 2000

Swedish pharma sales rose 11.2% in 1999

6 March 2000

Roche full-year 1999 sales up 12%, driven by the strong performance of

13 January 2000

Knoll's sibutramine still awaits Euro appros

11 January 2000

Goldman Sachs analysts review prospects for Japanese pharmaceutical firms

14 December 1999

Roche spinning off fragrances and flavors to form Givaudan, focus now on

6 December 1999

Stock Commentary Europe

25 November 1999

Xenical, Meridia drive US antiobesity drugmarket

15 November 1999

Pharmacopeia and Roche in obesity deal

18 October 1999

Roche revenues hit 20 billion Swiss francs

14 October 1999

Stock Commentary Europe

11 October 1999

On-line prices for Viagra and Propecia "higher than pharmacy," plus safety

11 October 1999

Gilead and Roche's flu drug approved in first market, Switzerland

24 September 1999

Xenical "reduces CV disease risk;" bosentan trial data

7 September 1999

Xenical "reduces CV disease risk"

3 September 1999

5% increase in sales as Tamro expands in Northern Europe

20 August 1999

Roche taken in hand over Xenical material

20 August 1999

Roche predicts strong full-year sales as net income increases 15%

19 August 1999

Strong performance expected for Roche's first half profits

16 August 1999

NICE sets out agenda for the evaluation of treatments in the UK

10 August 1999

UK's new PPRS provisions raise significant issues for industry, says

6 August 1999

BASF sees profits collapse as earnings are hit by vitamin price-fixing

6 August 1999

Lifestyle drugs "defined as a financial threat to the NHS," UK meeting hears

27 July 1999

Unspectacular first-half sales for Novartis, third-quarter pharma growth to

15 July 1999

Roche posts strong first-half 1999 sales, driven by high uptake of Xenical

13 July 1999

Stock Commentary Europe

8 July 1999

Swiss insurers lament Xenical reimbursement

6 July 1999

Fast progress for Vioxx and Xenical in USA

5 July 1999

Roche's Xenical Rxing in first six weeks

16 June 1999

Pharma to see "platinum age in 4th-qtr 1999," due to blockbusters, Y2K

11 June 1999

Further increase in Rxs for Roche's Xenical

2 June 1999

US Xenical Rxing up 48% in week to May 14

25 May 1999

Xenical prescribing takes off

20 May 1999

Worst may to be over for Europe's pharma stocks, but analysts remain

14 May 1999

Xenical gets off to strong start in USA

13 May 1999

Stock Commentary Europe

6 May 1999

Managed care firms ponder Xenical cover

5 May 1999

Stock Commentary Europe

29 April 1999

Alizyme to trial obesity drug next year

27 April 1999

Roche's obesity drug Xenical gains US approval earlier than forecast

27 April 1999

Swiss against health cover for Viagra

19 April 1999

Roche 1st qtr sales up 4%; Xenical doing well

15 April 1999

UK drug stock's rebound sustainable, says Commerzbank

13 April 1999

Roche reveals more than expected atannual general meeting

1 April 1999

Roche posts 3% profit rise, Fritz Gerber stepping down as chairman in 2001

10 March 1999

Future growth of the global pharmaceutical market evaluated by MSDW

23 February 1999

Roche launches Xenical in Brazil

4 February 1999

Stock Commentary Europe

28 January 1999

New UK obesity guidelines highlight role of drugs

25 January 1999

Two-year data support Xenical's efficacy

21 January 1999

Analysts not surprised by Roche results

15 January 1999

Roche posts strong sales increase for 1998, pharmaceutical turnover climbs

14 January 1999

Quality, not quantity, sums up New Chemical Entity launches in 1998

7 January 1999

Tasmar Suspended In Europe; Label Change Only In USA

18 November 1998

Roche Reports 32% Surge In 9 Months 1998 Sales

12 October 1998

Stock Commentary Europe

30 September 1998

Xenical Launched In UK And Germany

23 September 1998

First-Half Increase In Earnings At Roche

18 August 1998

Stock Commentary Europe

6 August 1998

BASF Grows On All Fronts, Pharma Sales Up 21%

4 August 1998

First European Launch Of Xenical In September

4 August 1998

Alizyme "Catapulted Into Clinical Arena"

23 July 1998

First Half Sales At Roche Leap 41%, Boosted By BM

13 July 1998

Stock Commentary Europe

25 June 1998

NIH Obesity Guidelines Define Role Of Drugs

25 June 1998

Better News For Roche As Xenical Sees First Launch

18 June 1998

Stock Commentary Europe

15 June 1998

Roche Withdraws Posicor On Drug Interaction Issue

15 June 1998

European And London Stock Comment

21 May 1998

Roche Moves A Step Closer To Xenical Approval In USA

14 May 1998

Xenical Recommended For Approval By CPMP

16 April 1998

Panel Split On Orlistat Approval For Obesity

16 March 1998

US Drugmakers Use Of Internet For Promotion

28 January 1998

Roche To Resubmit Xenical NDA

13 November 1997

Roche Share Price Dips On Xenical delay

29 August 1997

First Half Profit Growth At Roche

20 August 1997

First Launches For Roche's Posicor

24 July 1997

Long-Term Data With Roche's Xenical

24 July 1997

Solid First Half At Roche As Posicor Is Approved

16 July 1997

Outlook Favorable For Global Health Care

23 June 1997

EU/Austria Clash Over Roche Plant Subsidy

9 June 1997

Roche/Corange Deal Comfirms Global Strategy

9 June 1997

New Antiobesity Drug Regulations In UK

30 May 1997

European And London Stock Comment

26 May 1997

Showing 101-200 of 213 articles

Go to beginningPreviousNextGo to end